Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)
- Richard A Larson, MD
Richard A Larson, MD
- Editor-in-Chief — Hematology
- Section Editor — Leukemia
- Professor of Medicine
- University of Chicago Pritzker School of Medicine
ACUTE MYELOID LEUKEMIA OVERVIEW
Acute myeloid leukemia (AML) is a type of cancer of blood and bone marrow cells. It affects a group of white blood cells called myeloid cells. Normally, myeloid and other blood cells are produced in the bone marrow (the spongy area in the middle of bones) in a carefully controlled fashion. In someone with AML, the blood cell production process is abnormal and large numbers of immature myeloid cells are produced and may be released into the blood stream. Sometimes, the number of white blood cells in the circulation is abnormally high because of overproduction of malignant blood cells.
The overproduction of myeloid cells prevents the bone marrow from producing other important blood cells, including red blood cells, other types of white blood cells, and platelets. This results in a variety of body-wide symptoms, including anemia, bleeding, and an increased risk of infection.
GENERAL INFORMATION ABOUT ACUTE MYELOID LEUKEMIA TREATMENT
A number of chemotherapy medications are effective against AML. The goal of treatment is to kill the malignant cells without damaging the residual normal bone marrow cells. Studies are underway to find the best medicines, doses, and treatment schedules for AML.
Researchers have discovered that the genetic makeup of the abnormal myeloid cells can vary, which affects how you respond to treatment. Your treatment can be tailored based upon a careful analysis of your genetic material. These genetic changes are due to mutations that are acquired within bone marrow stem cells and thereby affect all of the daughter cells that are produced. It is not known how these mutations develop. They are generally not thought to be inherited but rather develop by chance. Treatment of AML depends upon your specific subtype of AML. For example, people with a certain type of AML, called “acute promyelocytic leukemia,” may be treated with other (non-chemotherapy) medications. Treatment also depends on your age (see 'Acute myeloid leukemia treatment in older people' below).
The usual treatment of AML is divided into two phases: induction of remission and postremission therapy.
INDUCTION OF REMISSION IN ACUTE MYELOID LEUKEMIA
The initial phase of treatment is referred to as remission induction or "induction" therapy. Induction therapy is given with the goal of decreasing the number of leukemia cells to an undetectable level and restoring the production of normal blood cells. Most of the cells in your body divide and multiply slowly and are not affected by chemotherapy. However, certain cells, such as those in the bone marrow (where the blood cells are produced), the hair follicles, and the cells lining the gastrointestinal (GI) tract are multiplying rapidly. As a result, chemotherapy is most likely to cause side effects such as anemia (lowered red blood cell count), susceptibility to infection (lowered white blood cell count or low hemoglobin level) and bleeding (lowered platelet count). Other side effects include temporary loss of hair, sores in the mouth, upset stomach, and diarrhea. (See "Induction therapy for acute myeloid leukemia in younger adults".)
The most common remission induction regimens include cytarabine, given continuously for seven days through an intravenous (IV) line. An anthracycline drug, such as daunorubicin or idarubicin, is also given in a single IV dose for the first three days of treatment. This is sometimes known as the "7+3" regimen. These drugs kill AML cells over the first 7 to 14 days; it then takes the normal bone marrow about 14 days to recover and produce normal blood cells again.
This phase of treatment takes approximately four weeks and is almost always performed while you stay in the hospital. The induction phase usually consists of one or two cycles. A cycle of chemotherapy refers to the time it takes to give the drugs and the time required for the body to recover.
Induction therapy frequently results in a complete remission of the AML, meaning that there are no visible leukemia cells in the blood or bone marrow when examined under a microscope and that the bone marrow is functioning normally. However, such remissions are usually short-lived unless additional, postremission therapy is given.
Complete remission — The first goal of AML treatment is to achieve a complete remission. Complete remission means that there is no visible evidence of leukemia cells in the blood or bone marrow and the bone marrow is functioning normally. A bone marrow biopsy and blood testing are done to determine when/if this occurs. Sensitive laboratory methods can detect leukemia that is not readily observed by a microscope; this is called minimal residual disease (MRD) and its persistence may impact additional treatment plans.
POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA
Post-remission therapy is given with the intention of killing leukemia cells that can remain in the bone marrow or blood, but are undetectable under the microscope. (See "Post-remission therapy for acute myeloid leukemia in younger adults".)
There are three basic treatment choices for post-remission therapy: additional chemotherapy, stem cell transplantation from a donor (allogeneic hematopoietic stem cell transplantation), or stem cell transplantation using your own stem cells (autologous hematopoietic stem cell transplantation). The "best" post-remission treatment depends upon several factors, including how aggressive or resistant to treatment the AML is:
●People with favorable risk disease are usually advised to continue with chemotherapy. Many of these patients are cured in this way.
●People with unfavorable risk disease are usually advised to have an allogeneic stem cell transplantation, if possible.
●The best treatment for intermediate risk disease is not clear; participation in a clinical trial is recommended, when possible. (See 'Clinical trials' below.)
Additional chemotherapy — Chemotherapy given after remission is called remission consolidation or postremission chemotherapy, and often includes high-dose cytarabine. Consolidation chemotherapy is usually given in the hospital over several days and repeated every four to six weeks. Consolidation chemotherapy is given for approximately four to six months.
Stem cell transplantation — Stem cell transplantation, also called bone marrow transplantation or hematopoietic cell transplantation (HCT), is a treatment in which you are given very high doses of chemotherapy or total body irradiation (TBI). This treatment is intended to kill cancer cells, but it also destroys all normal cells developing in the bone marrow. This means that your body's normal source of critical blood components (ie, the bone marrow) is no longer functional.
After the treatment, you must have a healthy supply of young blood cells (called stem cells) reintroduced, or transplanted using transfusion. The transplanted cells then re-establish the blood cell production process in the bone marrow. The new stem cells also generate a new immune system. (See "Patient information: Stem cell transplantation (bone marrow transplantation) (Beyond the Basics)".)
Stem cell transplantation is not recommended for all patients with AML. Serious, and sometimes even fatal, complications occur more commonly after stem cell transplantation than with chemotherapy. In certain groups of people, there is no clear benefit of stem cell transplantation over chemotherapy. However, transplantation may be appropriate in some people, such as those with more aggressive forms of AML, those who have had a relapse following remission, and those who do not achieve remission after initial induction therapy.
There are two main types of stem cell transplantation: allogeneic and autologous.
●Allogeneic transplantation uses stem cells from a healthy donor, ideally a sibling with a similar genetic makeup (called an HLA-matched related donor; MRD). "Allo" means "other." The HLA genes are inherited from both parents and govern your immune system. If you do not have a sibling with similar genetic characteristics, an unrelated person with a similar genetic makeup may be used (called a matched unrelated donor; MUD). Other possibilities include the use of a sibling with partially similar genetic characteristics (partially matched family member donor) or cord blood stem cells collected from a newborn's umbilical cord.
Allogeneic transplantation treats AML in two ways. First, high doses of chemotherapy or radiation are given immediately before the transplant, which kills the leukemia cells present in the blood and bone marrow that might be resistant to lower doses of chemotherapy. Second, when cells from another person are injected, the donor stem cells develop into immune cells that can identify the leukemia cells as foreign and launch an immune attack that helps destroy any remaining leukemia cells. This is called the "graft versus leukemia" or "graft versus tumor" effect.
Unfortunately, this response can lead to a complication called "graft versus host disease", in which the immune response includes an attack on your own healthy organs. Symptoms can include severe skin rash, diarrhea, liver damage, and other problems. Still, allogeneic transplantation is generally preferred over autologous transplantation in people with AML.
●In an autologous transplant, your own normal stem cells are collected while you are in complete remission. "Auto" means "self." Shortly afterwards, high dose chemotherapy or radiation is given. In some cases, the cells are treated to remove any lingering leukemia cells that may be present, although this is experimental. After the stem cells are collected, they are frozen for use at a later time. After your chemotherapy or radiation is complete, the harvested cells are thawed and returned by IV infusion.
Because the transplanted stem cells do not come from another person, there is no "graft versus host" disease. This helps reduce some of the side effects of treatment, but in general it also makes autologous transplantation somewhat less effective than allogeneic transplantation in fighting the leukemia, because of the lack of a "graft versus leukemia" effect. Autologous transplantation is less often recommended for treatment of AML for this reason.
ACUTE MYELOID LEUKEMIA TREATMENT IN OLDER PEOPLE
In general, people over 60 years old do not respond as well to treatment for AML. This is related to the following factors:
●Difficult-to-treat leukemia cells may be more common in older people. This means that the AML that occurs in older people tends to be more resistant to standard chemotherapy drugs.
●In older people, the presence of other disorders, such as diabetes, kidney, lung, or heart disease, increases the risk of treatment-related complications.
Treatment decisions for older people with AML are best made on a case by case basis. In otherwise healthy older people, even those >75 years of age, whose leukemia is not "high-risk" according to genetic testing, induction chemotherapy is generally recommended. (See "Treatment of acute myeloid leukemia in older adults".)
In older people with slowly progressing AML, severe underlying health problems, or high risk and unfavorable AML, the expected benefit of chemotherapy may not be worth the anticipated discomfort, hospitalization, and potentially toxic side effects. Less intensive chemotherapy regimens are under development for older patients and enrollment on a clinical trial of one of these regimens may be suggested. If the potential risk of chemotherapy is greater than the potential benefit, supportive care may be recommended. Supportive care generally includes blood transfusions for anemia and antibiotics as needed for infections.
Which treatment is right for me? — You and your family should get information from your healthcare provider about your type of AML, expected benefits of various treatments, possible side effects and toxicities, and your long-term outlook. These discussions are critical to determining the best course of action for you. Many new drugs or drug combinations are currently being studied for patients with AML. The best treatment for you may include a clinical trial so that you can have access to the latest new drugs.
TREATMENT OF RELAPSED OR RESISTANT ACUTE MYELOID LEUKEMIA
A limited number of treatments are effective in the treatment of AML. Thus, if your AML does not respond to or if your AML relapses after initial chemotherapy, management is more difficult:
●Approximately 50 percent of people with long first remissions (greater than one year) benefit from a second remission induction attempt with daunorubicin and cytarabine or with high-dose cytarabine (HDAC), but the duration of the second remission is usually shorter than the first. Because of this, stem cell transplantation should be considered for anyone who relapses after his or her initial treatment (once a second complete or partial remission is obtained).
●People who relapse within 12 months of their initial diagnosis usually have AML with a high degree of drug resistance and therefore have a lower rate of achieving a second complete remission. Medicines specifically approved for use in patients with relapsed AML or experimental agents may be useful in this setting, followed by stem cell transplantation if a remission occurs.
More detailed information is available by subscription. (See "Treatment of relapsed or refractory acute myeloid leukemia".)
LONG TERM MONITORING OF ACUTE MYELOID LEUKEMIA
Once you are in complete remission and have completed post-remission therapy, you will need long term monitoring so that any relapse can be detected and treated. Relapse is most likely to occur within the first two years after completion of induction chemotherapy, and becomes less common later.
Prognosis — Your chances of being cured of AML depend upon a number of factors, including your age, other health conditions, how aggressive your AML is, and whether you have been treated with chemotherapy before your AML diagnosis. In one study, approximately 65, 40, and 15 percent of people with favorable, intermediate, and unfavorable risk disease, respectively, were alive five years after diagnosis.
However, when discussing chances of cure, it is important to remember that these numbers represent averages and do not necessarily predict what will happen to you. A complete discussion of prognosis of AML is available separately. (See "Prognosis of acute myeloid leukemia".)
Many patients with leukemia will be asked to enroll in a clinical (research) trial. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask your doctor for more information, or read about clinical trials at:
Videos addressing common questions about clinical trials are available from the American Society of Clinical Oncology (http://www.cancer.net/pre-act).
WHERE TO GET MORE INFORMATION
Your healthcare provider is the best source of information for questions and concerns related to your medical problem.
This article will be updated as needed on our website (www.uptodate.com/patients). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.
Patient level information — UpToDate offers two types of patient education materials.
The Basics — The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.
Patient information: Acute myeloid leukemia (AML) (The Basics)
Patient information: Leukemia in adults (The Basics)
Patient information: Neutropenia and fever in people being treated for cancer (The Basics)
Beyond the Basics — Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.
Professional level information — Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.
Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia
Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults
Cytogenetics in acute myeloid leukemia
Induction therapy for acute myeloid leukemia in younger adults
Initial treatment of acute promyelocytic leukemia in adults
Molecular biology of acute promyelocytic leukemia
Molecular genetics of acute myeloid leukemia
Overview of the complications of acute myeloid leukemia
Pathogenesis of acute myeloid leukemia
Post-remission therapy for acute myeloid leukemia in younger adults
Prognosis of acute myeloid leukemia
Remission criteria in acute myeloid leukemia and monitoring for residual disease
Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome
Treatment of acute myeloid leukemia in older adults
Treatment of relapsed or refractory acute myeloid leukemia
Treatment of relapsed or refractory acute promyelocytic leukemia in adults
The following organizations also provide reliable health information.
●National Library of Medicine
●National Cancer Institute
●American Cancer Society
●The Leukemia & Lymphoma Society
●National Marrow Donor Program
●The American Society of Clinical Oncology
●The American Society of Hematology
- Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 2015; 373:1136.
- Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Hematology Am Soc Hematol Educ Program 2014; 2014:222.
- Roboz GJ. Epigenetic targeting and personalized approaches for AML. Hematology Am Soc Hematol Educ Program 2014; 2014:44.
- Döhner K, Paschka P. Intermediate-risk acute myeloid leukemia therapy: current and future. Hematology Am Soc Hematol Educ Program 2014; 2014:34.
- Sorror ML, Estey E. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program 2014; 2014:21.
- Wang ES. Treating acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program 2014; 2014:14.
- Klepin HD. Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2014; 2014:8.
All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.
- ACUTE MYELOID LEUKEMIA OVERVIEW
- GENERAL INFORMATION ABOUT ACUTE MYELOID LEUKEMIA TREATMENT
- INDUCTION OF REMISSION IN ACUTE MYELOID LEUKEMIA
- POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA
- ACUTE MYELOID LEUKEMIA TREATMENT IN OLDER PEOPLE
- TREATMENT OF RELAPSED OR RESISTANT ACUTE MYELOID LEUKEMIA
- LONG TERM MONITORING OF ACUTE MYELOID LEUKEMIA
- CLINICAL TRIALS
- WHERE TO GET MORE INFORMATION